Navigation Links
Cell pathway on overdrive prevents cancer response to dietary restriction
Date:3/11/2009

r size and incidence. However, some cancers' growth rate was unaffected by a decrease in food consumption. The reason for this difference remained unclear.

To determine how various tumor types are affected by dietary resistance, Kalaany injected cells from human prostate, breast, brain, and colon cancers into mice in an experimental protocol used frequently to study human cancers. The mice then ate as much as they liked (control group) or received 60% of the caloric intake of their counterparts (the dietary restriction (DR) group). Both groups ingested the same amounts of vitamins and minerals. After a few weeks, Kalaany saw that the cancers could be divided into DR-sensitive tumors, with significantly lower tumor volumes in the DR mice than in control mice, or DR-resistant tumors, whose sizes were apparently unaffected by normal or restricted diets.

Kalaany then grew the same cancer cells in Petri dishes to see how the DR-sensitive and DR-resistant cancers respond to food-related hormones in the body. The cancers were grown solutions containing increasing amounts of insulin, insulin-like growth factor 1 (IGF1) or in a solution without these hormones. The results supported the previous experiment: those cancer cells that were DR-sensitive in the mice were also stunted by a lack of insulin and IGF1; those cancer cells that were DR-resistant in the mice were unaffected by changes in insulin and IGF1 levels.

Because the difference between the two groups was sensitivity or insensitivity to insulin and IGF1, Kalaany thought the insensitive tumors may have something amiss in a cellular process called the PI3K pathway, which is activated by insulin/IGF1. A search for mutations in two genes found in the PI3K pathway that are often associated with cancer (PI3KCA and PTEN), revealed that DR-resistant cells had mutations in one or the other of the genes, while DR-sensitive cells showed no such mutations.

Using a DR-resistant tumor cell li
'/>"/>

Contact: Nicole Giese
giese@wi.mit.edu
617-258-6851
Whitehead Institute for Biomedical Research
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Pathway links inflammation, angiogenesis and breast cancer
2. Pathway Diagnostics Announces Commercial Availability of SensiTrop(TM) HIV Co-receptor Tropism Assay
3. Pathway to cell death redefined in landmark study
4. Pathway to cell death redefined in landmark study
5. Second pathway behind HIV-associated immune system dysfunction identified
6. Cell pathway, disease linked to histone action
7. Quest Diagnostics Licenses Technology Underlying SensiTrop(TM) HIV Co-Receptor Tropism Test from Pathway Diagnostics
8. Jefferson scientists uncover key pathway, potential drug targets in autoinflammatory disease
9. Anticancer Drugs Targeting the ErbB (EGFr/HEr2) Pathway Alone Generated Global Sales of Nearly $5 Billion in the First Nine Months of 2007
10. UC Davis researchers discover novel pathway to increased inflammation in diabetes patients
11. UC Davis researchers identify a cellular pathway that makes prostate cancer fatal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... 03, 2015 On February 21st, the ... fabulous EcoLuxe Lounge, a day-long event that features a ... products and services. Organized by Debbie Durkin and Durkin ... placement producer, the EcoLuxe Lounge saw many notable attendees. ... on General Hospital, The Flash, Star Trek: Deep Space ...
(Date:3/3/2015)... CA (PRWEB) March 03, 2015 Findings ... , Researchers at UC Davis have developed and characterized ... cancer cells, causing them to self-destruct. This novel mechanism ... responsible for a usually fatal type of brain cancer ... cancers. , The article, to be published in ...
(Date:3/3/2015)... The Rheumatology Nurses Society (RNS) ... care and safe practice for patients with rheumatic diseases. ... biologic infusions are administered in an infusion center, provider’s ... registered nurse (RN), as defined in their State Nurse ... patients receiving these medications during a first infusion, as ...
(Date:3/3/2015)... TX (PRWEB) March 04, 2015 The ... information on the therapeutic development for Alopecia. Alopecia is ... are the two main types of alopecia. Causes for ... disorder. Symptoms of alopecia may include male pattern hair ... broken hair. Alopecia can be classified as focal or ...
(Date:3/3/2015)... March 03, 2015 Daylight Savings Time may ... Kothare, MD, has tips for parents. , Parents and their ... at 2:00 a.m. when they set their clocks forward one ... up that day -- one hour earlier -- you will ... parents should start thinking about “sleep hygiene” for their kids ...
Breaking Medicine News(10 mins):Health News:Hollywood Star Chase Masterson and Choices Recovery Discuss Substance Abuse and Treatment at 2015 Oscars 2Health News:News: UC Davis Scientists Describe Novel Drug Mechanism That Fights Brain Cancer 2Health News:News: UC Davis Scientists Describe Novel Drug Mechanism That Fights Brain Cancer 3Health News:News: UC Davis Scientists Describe Novel Drug Mechanism That Fights Brain Cancer 4Health News:Administration of Biologic Infusions: A Position Statement of the Rheumatology Nurses Society 2Health News:Alopecia Therapeutics Drugs and Companies Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com 2Health News:Alopecia Therapeutics Drugs and Companies Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com 3Health News:Alopecia Therapeutics Drugs and Companies Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com 4Health News:Don’t Let Daylight Savings Disrupt Your Child’s Sleep 2
... Researchers at The Wistar Institute announce the discovery of ... with human papillomavirus (HPV). Their results, in both ... inhibitors protect a tumor-suppressing protein targeted by viral proteins, ... scientists presented their findings in the April 20 issue ...
... are testing whether different doses of an established blood pressure ... in people with mild hypertension, possibly with fewer side effects ... funded with a $1.9 million grant from the National Heart ... in the United States. The study drug, carvedilol ...
... April 26 (HealthDay News) -- The fourth National Prescription Drug ... 2 p.m., the U.S. Drug Enforcement Administration says. The ... and unused prescription drugs. At the third Take-Back Day ... tons) of unwanted or expired medications at more than 5,300 ...
... WEDNESDAY, April 25 (HealthDay News) -- Urban areas contaminated decades ... of aggravated assault, according to a new study. The ... dust emitted from older vehicles that ran on leaded gasoline, ... paint could have played a role as well. ...
... rs1051730-rs16969968 genotype and objective measures of tobacco exposure, which ... entirely, mediated by level of tobacco exposure, according to ... of the National Cancer Institute . The rs1051730-rs16969968 ... smoking, lung cancer risk, and other smoking-related outcomes. Prior ...
... are proposing a new model of care collaboration ... with various emergent cardiovascular conditions which require rapid, ... mortality, in an article published April 24 in ... ST-segment elevation myocardial infarction (STEMI), non-STEMI/unstable angina, out-of-hospital ...
Cached Medicine News:Health News:Small molecular bodyguards kill HPV-infected cancer cells by protecting tumor-suppressor 2Health News:Small molecular bodyguards kill HPV-infected cancer cells by protecting tumor-suppressor 3Health News:URMC clinical trial tests new regimen for hypertension 2Health News:Leaded Gas Exposure Linked to Later Violence: Study 2Health News:Genetic variants, tobacco exposure and lung cancer risk 2Health News:Is it time for regional cardiovascular emergency care systems across the US? 2
(Date:3/3/2015)... March 3, 2015  American Biosurgical, LLC ("ABI") ... cable manufacturer actively engaged in the design, development ... the world,s leading medical device companies has announced ... low volume custom medical cable manufacturer based in ... MTI brand under the name MTI Medical Cables.  ...
(Date:3/3/2015)... -- Columbia Laboratories, Inc. (Nasdaq: CBRX ) (" ... pharmaceutical company focused on pharmaceuticals for women,s health, today ... ROTH Conference, which will take place from March 8-11 ... Point, California . Management,s presentation will take place ... (12:00 p.m. Eastern Time) in the Promenade room. ...
(Date:3/3/2015)... - Sante Medical Hair Restoration is now offering the ... The ARTAS Robotic System is a state-of-the-art ... for transplantation. This latest development in minimally-invasive hair ... linear scar. "The ARTAS technology extends ... surgery." says Dr. Louis Grondin , Medical ...
Breaking Medicine Technology:American Biosurgical Acquires MTI Corporation 2No linear scar. Permanent results. 2
... Children,s Oncology Group Report Shows the Addition of ... of Death by 30% in Osteosarcoma Patients, ... IDMI ) today announced the Journal of ... 3 mifamurtide (L-MTP-PE) clinical trial,(INT-0133), entitled "Osteosarcoma: The ...
... Show Subjects Receiving,Infrequently Administered Ustekinumab Maintained Improvement from Psoriasis ... ... SAN ANTONIO, Feb. 2 One-year data from a second,double-blind, ... weeks provided sustained, clinically meaningful,improvement in the treatment of moderate ...
Cached Medicine Technology:IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology 2IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology 3IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology 4IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology 5IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology 6IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology 7Ustekinumab (CNTO 1275) Phase 3 Data Show Long-Term Improvement Of Chronic Plaque Psoriasis 2Ustekinumab (CNTO 1275) Phase 3 Data Show Long-Term Improvement Of Chronic Plaque Psoriasis 3Ustekinumab (CNTO 1275) Phase 3 Data Show Long-Term Improvement Of Chronic Plaque Psoriasis 4Ustekinumab (CNTO 1275) Phase 3 Data Show Long-Term Improvement Of Chronic Plaque Psoriasis 5
... low cost, low volume alternative. Whole blood is ... separated from whole blood by centrifugation in a ... the Cebus single use cartridge. The cartridge is ... activate the concentrating process. Finally, the cartridge is ...
Avitene Microfibrillar Collagen Hemostat (MCH) is used in surgical procedures as an to hemostasis when control of bleeding by ligature or conventional procedures is ineffective or impractical....
... device restores lordosis and ... less reaming of the ... Danek's Tapered Laparoscopic Instruments ... and reproducibly place the ...
3D Cranial is the most widely used surgical navigation software. Navigate with confidence and ease with displayed Zone of Accuracy and several fully automated features. 3D Cranial offers seamless int...
Medicine Products: